Scholarlink

Background <p>Pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE) represents a significant complication with incompletely understood pathogenesis. Notably, podocytic infolding glomerulopathy (PIG), a rare pathological phenomenon in SLE-related renal lesions, has not been previously linked to PAH development. The cardiovascular safety profile of belimumab, a biologic agent for SLE treatment, requires continued surveillance, particularly regarding potential pulmonary vascular complications.</p> Case presentation <p>We report a 30-year-old male with SLE who unexpectedly developed severe PAH following complete remission of class V lupus nephritis. The patient’s renal pathology exhibited PIG features, initially overlooked at diagnosis. Despite rapid improvement in renal function with conventional immunosuppression, PAH persisted, suggesting the critical role of vascular remodeling in PAH perpetuation. Glucocorticoid therapy resulted in avascular necrosis of the femoral head. Notably, PAH emerged during belimumab treatment and showed remarkable improvement following belimumab discontinuation, raising important concerns about potential therapy-related cardiovascular complications. Pulmonary arterial pressure significantly decreased with marked symptomatic improvement.</p> Conclusion <p>This case underscores the necessity for clinical vigilance in SLE management.For patients with SLE-PIG, close monitoring for potential PAH development is essential, even after apparent SLE remission. Most critically, this case highlights potential cardiovascular safety signals associated with belimumab therapy, emphasizing the need for systematic monitoring of pulmonary vascular complications in patients receiving novel biologic treatments—an observation warranting urgent verification in future clinical investigations.</p> Clinical trial number <p>Not applicable.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Severe pulmonary arterial hypertension development despite lupus nephritis remission: association with podocytic infolding glomerulopathy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月30日

查看全文
  • Li Qiu,
  • Binsan Huang,
  • Qiaozhen Liao,
  • Chenglun Li,
  • Azhen Wang,
  • Hao Li,
  • Qiongqiong Yang,
  • Yufeng Liang

摘要

Background

Pulmonary arterial hypertension (PAH) associated with systemic lupus erythematosus (SLE) represents a significant complication with incompletely understood pathogenesis. Notably, podocytic infolding glomerulopathy (PIG), a rare pathological phenomenon in SLE-related renal lesions, has not been previously linked to PAH development. The cardiovascular safety profile of belimumab, a biologic agent for SLE treatment, requires continued surveillance, particularly regarding potential pulmonary vascular complications.

Case presentation

We report a 30-year-old male with SLE who unexpectedly developed severe PAH following complete remission of class V lupus nephritis. The patient’s renal pathology exhibited PIG features, initially overlooked at diagnosis. Despite rapid improvement in renal function with conventional immunosuppression, PAH persisted, suggesting the critical role of vascular remodeling in PAH perpetuation. Glucocorticoid therapy resulted in avascular necrosis of the femoral head. Notably, PAH emerged during belimumab treatment and showed remarkable improvement following belimumab discontinuation, raising important concerns about potential therapy-related cardiovascular complications. Pulmonary arterial pressure significantly decreased with marked symptomatic improvement.

Conclusion

This case underscores the necessity for clinical vigilance in SLE management.For patients with SLE-PIG, close monitoring for potential PAH development is essential, even after apparent SLE remission. Most critically, this case highlights potential cardiovascular safety signals associated with belimumab therapy, emphasizing the need for systematic monitoring of pulmonary vascular complications in patients receiving novel biologic treatments—an observation warranting urgent verification in future clinical investigations.

Clinical trial number

Not applicable.